Cassava Sciences, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 26, 2021.

If you purchased Cassava Sciences securities and would like to join the action, please click “Join This Class Action.”

Class Period:February 2, 2021 through August 24, 2021
If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of the case:

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:

  • the quality and integrity of the scientific data supporting Cassava Sciences’ claims for the efficacy of simufilam, a small molecule drug designed to treat Alzheimer’s disease, had been overstated;
  • the scientific data supporting Cassava Sciences’ claims for simufilam’s efficacy were biased; and
  • as a result of the foregoing, defendants’ positive statements during the Class Period about the Company’s business metrics and financial prospects and the likelihood of U.S. Food and Drug Administration (“FDA”) approval were false and misleading and/or lacked a reasonable basis.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Follow us on:

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top